<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Microbiol Antimicrob</journal-id><journal-title>Annals of Clinical Microbiology and Antimicrobials</journal-title><issn pub-type="epub">1476-0711</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15601468</article-id><article-id pub-id-type="pmc">544565</article-id><article-id pub-id-type="publisher-id">1476-0711-3-26</article-id><article-id pub-id-type="doi">10.1186/1476-0711-3-26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Organisms isolated from adults with Cystic Fibrosis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>McManus</surname><given-names>Terence E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>TerryMcManus@doctors.org.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>McDowell</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>a.mcdowell@qub.ac.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Moore</surname><given-names>John E</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>JeMoore@niphl.dnet.co.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Elborn</surname><given-names>Stuart J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stuart.elborn@bch.n-i.nhs</email></contrib></contrib-group><aff id="I1"><label>1</label>Regional Adult Cystic Fibrosis Center, Belfast City Hospital, Belfast, Northern Ireland, BT9 7AB, UK</aff><aff id="I2"><label>2</label>Department of Bacteriology, Belfast City Hospital, Belfast, Northern Ireland, BT9 7AB, UK</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2004</year></pub-date><volume>3</volume><fpage>26</fpage><lpage>26</lpage><ext-link ext-link-type="uri" xlink:href="http://www.ann-clinmicrob.com/content/3/1/26"></ext-link><history><date date-type="received"><day>27</day><month>8</month><year>2004</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2004</year></date></history><permissions><copyright-statement>Copyright © 2004 McManus et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>McManus et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3178" xml_f="3188" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3199" xml_f="3478" txt_i="22" txt_f="301">Patients with cystic fibrosis [CF] have frequent pulmonary exacerbations associated with the isolation of bacterial organisms from sputum samples. It is not clear however, if there are differences in the types of additional organisms isolated from patients who are infected with </offsets><italic><offsets xml_i="3486" xml_f="3507" txt_i="301" txt_f="322">Burkholderia cepacia </offsets></italic><offsets xml_i="3516" xml_f="3533" txt_i="322" txt_f="339">complex [BCC] or </offsets><italic><offsets xml_i="3541" xml_f="3564" txt_i="339" txt_f="362">Pseudomonas aerugionsa </offsets></italic><offsets xml_i="3573" xml_f="3658" txt_i="362" txt_f="447">[PA] in comparison to those who are not infected with either of these organisms [NI].</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3699" xml_f="3706" txt_i="449" txt_f="456">Methods</offsets></title><p><offsets xml_i="3717" xml_f="4018" txt_i="457" txt_f="758">Adult patients attending the regional CF unit were followed over a two year period and patients were assigned to three groups depending on whether they were known to be chronically infected with BCC, PA or NI. We compared the numbers and types of organisms which were isolated in each of these groups.</offsets></p></sec><sec><title><offsets xml_i="4040" xml_f="4047" txt_i="760" txt_f="767">Results</offsets></title><p><offsets xml_i="4058" xml_f="4492" txt_i="768" txt_f="1199">Information was available on a total of 79 patients; BCC 23, PA 30 and NI 26. Total numbers of organisms isolated, expressed as median and IQR for each group, [P = 0.045] and numbers of co-infecting organisms [P = 0.003] were significantly higher in the BCC group compared to PA, and in the PA group [P &lt; 0.001, p = 0.007 respectively] compared to NI patients. The pattern of co-infecting organisms was similar in all three groups.</offsets></p></sec><sec><title><offsets xml_i="4514" xml_f="4525" txt_i="1201" txt_f="1212">Conclusions</offsets></title><p><offsets xml_i="4536" xml_f="4784" txt_i="1213" txt_f="1461">Total numbers of organisms isolated and numbers of co-infecting organisms were significantly higher in the BCC group compared to PA, and in the PA group compared to NI patients. Types of co-infecting organisms are similar in all groups of patients.</offsets></p></sec></abstract><kwd-group><kwd>Cystic Fibrosis</kwd><kwd>Bacterial Infection</kwd><kwd>Antibiotics</kwd><kwd><italic>Burkholderia cepacia complex</italic></kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5053" xml_f="5065" txt_i="1470" txt_f="1482">Introduction</offsets></title><p><offsets xml_i="5076" xml_f="5229" txt_i="1483" txt_f="1636">Patients with CF experience frequent exacerbations of their symptoms; contributing factors include infections which may be bacterial or viral in nature [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5260" xml_f="5261" txt_i="1636" txt_f="1637">1</offsets></xref><offsets xml_i="5268" xml_f="5269" txt_i="1637" txt_f="1638">-</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5300" xml_f="5301" txt_i="1638" txt_f="1639">3</offsets></xref><offsets xml_i="5308" xml_f="5503" txt_i="1639" txt_f="1834">]. Exacerbations which are associated with the identification of an infecting organism are associated with a more rapid decline in lung function, admission to hospital and earlier acquisition of </offsets><italic><offsets xml_i="5511" xml_f="5525" txt_i="1834" txt_f="1848">P. aeruginosa </offsets></italic><offsets xml_i="5534" xml_f="5540" txt_i="1848" txt_f="1854">[PA] [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5571" xml_f="5572" txt_i="1854" txt_f="1855">4</offsets></xref><offsets xml_i="5579" xml_f="5580" txt_i="1855" txt_f="1856">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5611" xml_f="5612" txt_i="1856" txt_f="1857">6</offsets></xref><offsets xml_i="5619" xml_f="5681" txt_i="1857" txt_f="1919">]. It is also known that those patients who are infected with </offsets><italic><offsets xml_i="5689" xml_f="5708" txt_i="1919" txt_f="1938">B. cepacia complex </offsets></italic><offsets xml_i="5717" xml_f="5820" txt_i="1938" txt_f="2041">[BCC] have a worse prognosis and often a more rapid decline in lung function with increased mortality [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5851" xml_f="5852" txt_i="2041" txt_f="2042">7</offsets></xref><offsets xml_i="5859" xml_f="5943" txt_i="2042" txt_f="2126">]. Previous investigators examining pathogens infecting the CF lung have identified </offsets><italic><offsets xml_i="5951" xml_f="5964" txt_i="2126" txt_f="2139">P. aeruginosa</offsets></italic><offsets xml_i="5973" xml_f="5975" txt_i="2139" txt_f="2141">, </offsets><italic><offsets xml_i="5983" xml_f="5992" txt_i="2141" txt_f="2150">S. aureus</offsets></italic><offsets xml_i="6001" xml_f="6003" txt_i="2150" txt_f="2152">, </offsets><italic><offsets xml_i="6011" xml_f="6024" txt_i="2152" txt_f="2165">H. influenzae</offsets></italic><offsets xml_i="6033" xml_f="6035" txt_i="2165" txt_f="2167">, </offsets><italic><offsets xml_i="6043" xml_f="6057" txt_i="2167" txt_f="2181">S. maltophilia</offsets></italic><offsets xml_i="6066" xml_f="6068" txt_i="2181" txt_f="2183">, </offsets><italic><offsets xml_i="6076" xml_f="6092" txt_i="2183" txt_f="2199">A. xylosoxidans </offsets></italic><offsets xml_i="6101" xml_f="6105" txt_i="2199" txt_f="2203">and </offsets><italic><offsets xml_i="6113" xml_f="6133" txt_i="2203" txt_f="2223">Aspergillus species </offsets></italic><offsets xml_i="6142" xml_f="6172" txt_i="2223" txt_f="2253">as being important pathogens [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6203" xml_f="6204" txt_i="2253" txt_f="2254">1</offsets></xref><offsets xml_i="6211" xml_f="6212" txt_i="2254" txt_f="2255">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6243" xml_f="6244" txt_i="2255" txt_f="2256">8</offsets></xref><offsets xml_i="6251" xml_f="6253" txt_i="2256" txt_f="2258">].</offsets></p><p><offsets xml_i="6260" xml_f="6657" txt_i="2259" txt_f="2656">This study examines the bacterial organisms cultured from an adult CF population, subdividing them into three groups; BCC, PA and those who were not infected with either of these organisms [NI] and to correlate with several clinical parameters. We hypothesized that those patients with BCC have more co-infection with other bacteria and this contributes to the greater morbidity in these patients.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="6708" xml_f="6729" txt_i="2658" txt_f="2679">Materials and Methods</offsets></title><sec><title><offsets xml_i="6749" xml_f="6777" txt_i="2680" txt_f="2708">Study Design and Eligibility</offsets></title><p><offsets xml_i="6788" xml_f="7507" txt_i="2709" txt_f="3421">Data were collected on all patients [&gt;18 years old] attending the regional adult CF unit at the Belfast City Hospital for two consecutive years. Sputum specimens were obtained for each patient at regular clinic attendances [patients were reviewed at 3 monthly intervals] as well as twice during hospital admissions. BCC was cultured from sputum employing selective agar (Columbian Agar Base cat no: CM331, Oxoid Ltd., Hampshire + 5% Defibrinated Horse Blood E &amp; O Laboratories, Bonnybridge, Scotland). All isolates were grouped into cultural phenotypes displaying similar visual characteristics and one colony from each phenotype identified by API. Sputum samples were well taken samples following physiotherapy.</offsets></p><p><offsets xml_i="7514" xml_f="8382" txt_i="3422" txt_f="4290">Sputum culture results were retrieved from the Bacteriology database for all samples submitted over the study time period. Patients were then divided into three groups using the following criteria; BCC if there was ever any sputum culture positive for these organisms. PA, if this bacterium was identified on two or more occasions over a twelve month period, and NI for all other patients who were not chronically infected with either of these organisms. It was noted as to whether the positive culture consisted of one organism or if there were additional organisms identified. In the BCC and PA groups, when more than one organism was identified from a sputum culture the additional organism [s] where recorded as 'co-infecting', as where all organisms in cultures of two or more infecting organisms in the NI group. Co-infecting organisms were divided into groups; </offsets><italic><offsets xml_i="8390" xml_f="8403" txt_i="4290" txt_f="4303">P. aeruginosa</offsets></italic><offsets xml_i="8412" xml_f="8414" txt_i="4303" txt_f="4305">, </offsets><italic><offsets xml_i="8422" xml_f="8431" txt_i="4305" txt_f="4314">S. aureus</offsets></italic><offsets xml_i="8440" xml_f="8442" txt_i="4314" txt_f="4316">, </offsets><italic><offsets xml_i="8450" xml_f="8462" txt_i="4316" txt_f="4328">H. influenza</offsets></italic><offsets xml_i="8471" xml_f="8473" txt_i="4328" txt_f="4330">, </offsets><italic><offsets xml_i="8481" xml_f="8493" txt_i="4330" txt_f="4342">S. pneumonia</offsets></italic><offsets xml_i="8502" xml_f="8504" txt_i="4342" txt_f="4344">, </offsets><italic><offsets xml_i="8512" xml_f="8527" txt_i="4344" txt_f="4359">S. maltophilia </offsets></italic><offsets xml_i="8536" xml_f="8672" txt_i="4359" txt_f="4495">and all other organisms including fungi. The facility to detect respiratory viral infection was not available at the time of this study.</offsets></p><p><offsets xml_i="8679" xml_f="9068" txt_i="4496" txt_f="4885">Spirometry [Vitalograph α ,Buckingham, UK] and oxygen saturation measurements were noted at the start and end of the study as well as the best measurement for each year. Weight was recorded at the beginning and end of the two year period. Other measurements included; smoking history, use of prophylactic and number of courses of intravenous antibiotics and a history of diabetes mellitus.</offsets></p></sec><sec><title><offsets xml_i="9090" xml_f="9110" txt_i="4887" txt_f="4907">Statistical Analysis</offsets></title><p><offsets xml_i="9121" xml_f="9653" txt_i="4908" txt_f="5440">Statistical analyses were performed using the SPSS version 11 package. The Chi-square test was used to analyse differences in the sex, smoking status and incidence of diabetes mellitus between groups. The Kruskal-Wallis and Mann Whitney test were used to compare antibiotic use and organisms isolated across groups. Lung Function and Oxygen saturation means were compared by one-way analysis of variance followed by the Student-Newman-Keuls method. A probability (P) value of less than 0.05 was considered statistically significant.</offsets></p></sec></sec><sec><title><offsets xml_i="9681" xml_f="9688" txt_i="5443" txt_f="5450">Results</offsets></title><p><offsets xml_i="9699" xml_f="9847" txt_i="5451" txt_f="5599">Information was available on a total of 79 patients, mean [Standard Deviation] age 26 [7.9] years. Numbers in each group were as follows; BCC 23 [2 </offsets><italic><offsets xml_i="9855" xml_f="9879" txt_i="5599" txt_f="5623">Burkholderia multivorans</offsets></italic><offsets xml_i="9888" xml_f="9893" txt_i="5623" txt_f="5628">, 21 </offsets><italic><offsets xml_i="9901" xml_f="9925" txt_i="5628" txt_f="5652">Burkholderia cenocepacia</offsets></italic><offsets xml_i="9934" xml_f="10542" txt_i="5652" txt_f="6257">, all ET -12], PA 30 and NI 26. Those patients in the BCC group had a mean duration of infection of 67 months. There was no difference in the sex distribution between the groups, P = 0.18. There were a total of 10 [12.7%] patients with diabetes, but they had no relationship with the groupings [P = 0.19]. There were significantly more smokers in the BCC group [P = 0.005] in comparison to PA and NI. Prophylactic antibiotic use was similar throughout all groups, P = 0.14. Intravenous antibiotic use was similar in the BCC and PA patient groups but significantly higher compared to NI [P &lt; 0.001], table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="10574" xml_f="10575" txt_i="6257" txt_f="6258">1</offsets></xref><offsets xml_i="10582" xml_f="10916" txt_i="6258" txt_f="6589">. There was no difference in oral antibiotic use between the groups. Those patients in the BCC group had a significant reduction in their weight compared to the PA and NI groups (P &lt; 0.05); there was an average weight loss of 1.1 Kg. Patients in the PA and NI groups gained weight, 0.69 ± 2.5 and 1.82 ± 2.7 kilograms respectively.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="10964" xml_f="10971" txt_i="6590" txt_f="6597">Table 1</offsets></label><caption><p><offsets xml_i="10991" xml_f="11061" txt_i="6597" txt_f="6667">Use of oral and intravenous antibiotics; median [Interquartile Range].</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><offsets xml_i="11148" xml_f="11166" txt_i="6668" txt_f="6686">Antibiotic Courses</offsets></bold></td><td align="center" colspan="3"><bold><offsets xml_i="11215" xml_f="11228" txt_i="6687" txt_f="6700">Patient Group</offsets></bold></td></tr><tr><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center"><bold><offsets xml_i="11331" xml_f="11334" txt_i="6704" txt_f="6707">BCC</offsets></bold></td><td align="center"><bold><offsets xml_i="11371" xml_f="11373" txt_i="6708" txt_f="6710">PA</offsets></bold></td><td align="center"><bold><offsets xml_i="11410" xml_f="11412" txt_i="6711" txt_f="6713">NI</offsets></bold></td></tr></thead><tbody><tr><td align="center"><bold><offsets xml_i="11473" xml_f="11488" txt_i="6714" txt_f="6729">No. of Patients</offsets></bold></td><td align="center"><offsets xml_i="11519" xml_f="11521" txt_i="6730" txt_f="6732">23</offsets></td><td align="center"><offsets xml_i="11545" xml_f="11547" txt_i="6733" txt_f="6735">30</offsets></td><td align="center"><offsets xml_i="11571" xml_f="11573" txt_i="6736" txt_f="6738">26</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="11612" xml_f="11616" txt_i="6739" txt_f="6743">Oral</offsets></bold></td><td align="center"><offsets xml_i="11647" xml_f="11656" txt_i="6744" txt_f="6753">0 [0–2.0]</offsets></td><td align="center"><offsets xml_i="11680" xml_f="11689" txt_i="6754" txt_f="6763">1 [0–2.0]</offsets></td><td align="center"><offsets xml_i="11713" xml_f="11722" txt_i="6764" txt_f="6773">1 [0–2.3]</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="11761" xml_f="11772" txt_i="6774" txt_f="6785">Intravenous</offsets></bold></td><td align="center"><offsets xml_i="11803" xml_f="11815" txt_i="6786" txt_f="6798">3 [1.0–11.0]</offsets></td><td align="center"><offsets xml_i="11839" xml_f="11850" txt_i="6799" txt_f="6810">3 [2.0–5.0]</offsets></td><td align="center"><offsets xml_i="11874" xml_f="11883" txt_i="6811" txt_f="6820">0 [0–2.0]</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="11925" xml_f="11957" txt_i="6821" txt_f="6853">The changes between the best FEV</offsets><sub><offsets xml_i="11962" xml_f="11964" txt_i="6853" txt_f="6855">1 </offsets></sub><offsets xml_i="11970" xml_f="12007" txt_i="6855" txt_f="6892">measured each year, the change in FEV</offsets><sub><offsets xml_i="12012" xml_f="12014" txt_i="6892" txt_f="6894">1 </offsets></sub><offsets xml_i="12020" xml_f="12275" txt_i="6894" txt_f="7149">between the start and end were not significant between the groups. Oxygen saturation measured at the end of the study tended to be lower in the BCC and PA groups when compared to the NI group; however there were no significant differences for the best SaO</offsets><sub><offsets xml_i="12280" xml_f="12282" txt_i="7149" txt_f="7151">2 </offsets></sub><offsets xml_i="12288" xml_f="12309" txt_i="7151" txt_f="7172">values for each year.</offsets></p><p><offsets xml_i="12316" xml_f="12476" txt_i="7173" txt_f="7333">Median and interquartile ranges of organism numbers [total numbers and numbers of co-infecting organisms] and specimen numbers in each group are shown in table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="12508" xml_f="12509" txt_i="7333" txt_f="7334">2</offsets></xref><offsets xml_i="12516" xml_f="13011" txt_i="7334" txt_f="7823"> along with details of the types of co-infecting organisms. Total numbers of organisms isolated, that is the number of isolates of different organisms, [P = 0.045] and numbers of co-infecting organisms [P = 0.003] were significantly higher in the BCC group compared to PA and in the PA group [P &lt; 0.001, P = 0.007] compared to NI. Total numbers of positive sputum cultures were greater in both the BCC and PA groups in comparison to NI [P &lt; 0.0001]. The pattern of co-infecting organisms, </offsets><italic><offsets xml_i="13019" xml_f="13040" txt_i="7823" txt_f="7844">Staphylococcus aureus</offsets></italic><offsets xml_i="13049" xml_f="13051" txt_i="7844" txt_f="7846">, </offsets><italic><offsets xml_i="13059" xml_f="13081" txt_i="7846" txt_f="7868">Haemophilus influenzae</offsets></italic><offsets xml_i="13090" xml_f="13092" txt_i="7868" txt_f="7870">, </offsets><italic><offsets xml_i="13100" xml_f="13124" txt_i="7870" txt_f="7894">Streptococcus pneumoniae</offsets></italic><offsets xml_i="13133" xml_f="13135" txt_i="7894" txt_f="7896">, </offsets><italic><offsets xml_i="13143" xml_f="13171" txt_i="7896" txt_f="7924">Stenotrophomonas maltophilia</offsets></italic><offsets xml_i="13180" xml_f="13225" txt_i="7924" txt_f="7969">, was similar in all three groups except for </offsets><italic><offsets xml_i="13233" xml_f="13247" txt_i="7969" txt_f="7983">P. aeruginosa </offsets></italic><offsets xml_i="13256" xml_f="13340" txt_i="7983" txt_f="8064">being more frequently detected in the BCC group in comparison to NI [p &lt; 0.0001].</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="13388" xml_f="13395" txt_i="8065" txt_f="8072">Table 2</offsets></label><caption><p><offsets xml_i="13415" xml_f="13660" txt_i="8072" txt_f="8317">Median [Interquartile Range] of numbers of sputum specimens, total numbers of organisms and numbers of co-infecting organisms [per patient] in each group. Mean ± SD numbers of individual co-infecting organisms isolated per patient in each group.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><offsets xml_i="13747" xml_f="13758" txt_i="8318" txt_f="8329">Measurement</offsets></bold></td><td align="center" colspan="3"><bold><offsets xml_i="13807" xml_f="13820" txt_i="8330" txt_f="8343">Patient Group</offsets></bold></td></tr><tr><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center"><bold><offsets xml_i="13923" xml_f="13926" txt_i="8347" txt_f="8350">BCC</offsets></bold></td><td align="center"><bold><offsets xml_i="13963" xml_f="13965" txt_i="8351" txt_f="8353">PA</offsets></bold></td><td align="center"><bold><offsets xml_i="14002" xml_f="14004" txt_i="8354" txt_f="8356">NI</offsets></bold></td></tr></thead><tbody><tr><td align="center"><bold><offsets xml_i="14065" xml_f="14080" txt_i="8357" txt_f="8372">No. of Patients</offsets></bold></td><td align="center"><offsets xml_i="14111" xml_f="14113" txt_i="8373" txt_f="8375">23</offsets></td><td align="center"><offsets xml_i="14137" xml_f="14139" txt_i="8376" txt_f="8378">30</offsets></td><td align="center"><offsets xml_i="14163" xml_f="14165" txt_i="8379" txt_f="8381">26</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="14204" xml_f="14236" txt_i="8382" txt_f="8414">Total No. of Specimens / patient</offsets></bold></td><td align="center"><offsets xml_i="14267" xml_f="14280" txt_i="8415" txt_f="8428">24 [9.0–59.0]</offsets></td><td align="center"><offsets xml_i="14304" xml_f="14319" txt_i="8429" txt_f="8444">19.5 [5.5–34.5]</offsets></td><td align="center"><offsets xml_i="14343" xml_f="14352" txt_i="8445" txt_f="8454">0 [0–9.8]</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="14391" xml_f="14425" txt_i="8455" txt_f="8489">Total No. of Organisms / patient †</offsets></bold></td><td align="center"><offsets xml_i="14456" xml_f="14470" txt_i="8490" txt_f="8504">32 [16.0–79.0]</offsets></td><td align="center"><offsets xml_i="14494" xml_f="14507" txt_i="8505" txt_f="8518">24 [7.8–46.3]</offsets></td><td align="center"><offsets xml_i="14531" xml_f="14541" txt_i="8519" txt_f="8529">0 [0–11.3]</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="14580" xml_f="14621" txt_i="8530" txt_f="8571">No. of Co-infecting Organisms / patient ‡</offsets></bold></td><td align="center"><offsets xml_i="14652" xml_f="14665" txt_i="8572" txt_f="8585">15 [8.0–20.0]</offsets></td><td align="center"><offsets xml_i="14689" xml_f="14703" txt_i="8586" txt_f="8600">3.5 [0.8–11.3]</offsets></td><td align="center"><offsets xml_i="14727" xml_f="14736" txt_i="8601" txt_f="8610">0 [0–4.3]</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="14775" xml_f="14801" txt_i="8611" txt_f="8637">P. aeruginosa co-infection</offsets></bold></td><td align="center"><offsets xml_i="14832" xml_f="14843" txt_i="8638" txt_f="8649">14.4 ± 19.7</offsets></td><td align="center"><offsets xml_i="14867" xml_f="14868" txt_i="8650" txt_f="8651">-</offsets></td><td align="center"><offsets xml_i="14892" xml_f="14901" txt_i="8652" txt_f="8661">0.1 ± 0.3</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="14940" xml_f="14962" txt_i="8662" txt_f="8684">S. aureus co-infection</offsets></bold></td><td align="center"><offsets xml_i="14993" xml_f="15002" txt_i="8685" txt_f="8694">3.6 ± 4.8</offsets></td><td align="center"><offsets xml_i="15026" xml_f="15035" txt_i="8695" txt_f="8704">2.0 ± 4.1</offsets></td><td align="center"><offsets xml_i="15059" xml_f="15068" txt_i="8705" txt_f="8714">3.7 ± 7.5</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="15107" xml_f="15132" txt_i="8715" txt_f="8740">H. influenza co-infection</offsets></bold></td><td align="center"><offsets xml_i="15163" xml_f="15172" txt_i="8741" txt_f="8750">1.8 ± 2.9</offsets></td><td align="center"><offsets xml_i="15196" xml_f="15205" txt_i="8751" txt_f="8760">0.7 ± 1.6</offsets></td><td align="center"><offsets xml_i="15229" xml_f="15238" txt_i="8761" txt_f="8770">1.1 ± 3.1</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="15277" xml_f="15302" txt_i="8771" txt_f="8796">S. pneumonia co-infection</offsets></bold></td><td align="center"><offsets xml_i="15333" xml_f="15342" txt_i="8797" txt_f="8806">0.6 ± 1.2</offsets></td><td align="center"><offsets xml_i="15366" xml_f="15375" txt_i="8807" txt_f="8816">0.2 ± 0.5</offsets></td><td align="center"><offsets xml_i="15399" xml_f="15408" txt_i="8817" txt_f="8826">0.4 ± 1.0</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="15447" xml_f="15474" txt_i="8827" txt_f="8854">S. maltophilia co-infection</offsets></bold></td><td align="center"><offsets xml_i="15505" xml_f="15514" txt_i="8855" txt_f="8864">0.9 ± 1.5</offsets></td><td align="center"><offsets xml_i="15538" xml_f="15547" txt_i="8865" txt_f="8874">2.6 ± 6.6</offsets></td><td align="center"><offsets xml_i="15571" xml_f="15580" txt_i="8875" txt_f="8884">1.7 ± 6.3</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="15619" xml_f="15646" txt_i="8885" txt_f="8912">Other organism co-infection</offsets></bold></td><td align="center"><offsets xml_i="15677" xml_f="15686" txt_i="8913" txt_f="8922">1.4 ± 1.9</offsets></td><td align="center"><offsets xml_i="15710" xml_f="15719" txt_i="8923" txt_f="8932">3.1 ± 5.9</offsets></td><td align="center"><offsets xml_i="15743" xml_f="15752" txt_i="8933" txt_f="8942">1.7 ± 3.2</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="15798" xml_f="15905" txt_i="8943" txt_f="9050">† Total number of different bacterial organisms isolated in that group of patients during the study period.</offsets></p><p><offsets xml_i="15912" xml_f="16055" txt_i="9051" txt_f="9194">‡ Number different bacterial organisms isolated excluding those isolates for BCC or PA in those patients who are colonized with these bacteria.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="16108" xml_f="16118" txt_i="9196" txt_f="9206">Discussion</offsets></title><p><offsets xml_i="16129" xml_f="16389" txt_i="9207" txt_f="9467">This study identified individuals with BCC and PA more frequently require courses of IV antibiotic therapy in comparison to CF adults in whom neither pathogen was identified [NI]. This is in keeping with previous findings in which patients colonized with BCC [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="16420" xml_f="16421" txt_i="9467" txt_f="9468">9</offsets></xref><offsets xml_i="16428" xml_f="16429" txt_i="9468" txt_f="9469">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="16461" xml_f="16463" txt_i="9469" txt_f="9471">10</offsets></xref><offsets xml_i="16470" xml_f="16480" txt_i="9471" txt_f="9481">] and PA [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="16512" xml_f="16514" txt_i="9481" txt_f="9483">11</offsets></xref><offsets xml_i="16521" xml_f="16522" txt_i="9483" txt_f="9484">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="16554" xml_f="16556" txt_i="9484" txt_f="9486">12</offsets></xref><offsets xml_i="16563" xml_f="16885" txt_i="9486" txt_f="9808">] were noted to have a more rapid decline in health status with an associated increased number of hospital admissions for treatment of infective exacerbations. Prophylactic antibiotic use was found to be similar in all groups, however their role and the optimal duration of treatment of CF patients remains controversial [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="16917" xml_f="16919" txt_i="9808" txt_f="9810">13</offsets></xref><offsets xml_i="16926" xml_f="16928" txt_i="9810" txt_f="9812">].</offsets></p><p><offsets xml_i="16935" xml_f="17108" txt_i="9813" txt_f="9986">The BCC group were also noted to have significant weight loss over the study period, again this has been shown to act as an independent predictor of survival in this group [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="17140" xml_f="17142" txt_i="9986" txt_f="9988">14</offsets></xref><offsets xml_i="17149" xml_f="17330" txt_i="9988" txt_f="10169">]. No significant differences were demonstrated between weight change in the PA and NI groups; it may be that a longer period of study is required to detect significant differences.</offsets></p><p><offsets xml_i="17337" xml_f="17461" txt_i="10170" txt_f="10294">On comparison of PA and BCC patients to those in the NI group, investigators have previously demonstrated higher morbidity [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="17493" xml_f="17495" txt_i="10294" txt_f="10296">10</offsets></xref><offsets xml_i="17502" xml_f="17503" txt_i="10296" txt_f="10297">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="17535" xml_f="17537" txt_i="10297" txt_f="10299">12</offsets></xref><offsets xml_i="17544" xml_f="17988" txt_i="10299" txt_f="10740">]. In this study we have found higher total numbers of positive sputum specimens, total numbers of organisms and increased numbers of co-infecting organisms in the BCC and PA groups in comparison to NI [P &lt; 0.01]. To our knowledge this is the first paper to relate bacterial colonization to the numbers and types of coinfecting organisms isolated during exacerbations. Patients infected with BCC are known to have elevated lung inflammation[</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="18020" xml_f="18022" txt_i="10740" txt_f="10742">15</offsets></xref><offsets xml_i="18029" xml_f="18081" txt_i="10742" txt_f="10794">] with an accelerated rate of lung function decline[</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="18112" xml_f="18113" txt_i="10794" txt_f="10795">9</offsets></xref><offsets xml_i="18120" xml_f="18249" txt_i="10795" txt_f="10924">], this in part may be due to BCC lipopolysaccharides mediated neutrophil recruitment and subsequent respiratory burst response [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="18281" xml_f="18283" txt_i="10924" txt_f="10926">16</offsets></xref><offsets xml_i="18290" xml_f="18457" txt_i="10926" txt_f="11093">]. This pro-inflammatory status may predispose individuals to increased morbidity and co-infection. BCC infection has also been linked to a compromised host response [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="18489" xml_f="18491" txt_i="11093" txt_f="11095">17</offsets></xref><offsets xml_i="18498" xml_f="18545" txt_i="11095" txt_f="11142">] and combined with a poor nutritional status [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="18577" xml_f="18579" txt_i="11142" txt_f="11144">14</offsets></xref><offsets xml_i="18586" xml_f="18818" txt_i="11144" txt_f="11376">] increases the likelihood of respiratory tract infection in these patients. In this study the types of organisms isolated did not differ significantly between the groups, organisms corresponding to those found on previous studies [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="18849" xml_f="18850" txt_i="11376" txt_f="11377">1</offsets></xref><offsets xml_i="18857" xml_f="19095" txt_i="11377" txt_f="11615">]. It should be borne in mind that these findings relate to the adult CF population in Northern Ireland which is unique in that the majority of B. cepacia complex positive patients are colonized with a single strain (B. cenocepacia ET12).</offsets></p><p><offsets xml_i="19102" xml_f="19197" txt_i="11616" txt_f="11711">It is well documented that CF patients experience a more rapid decline in their lung function [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="19229" xml_f="19231" txt_i="11711" txt_f="11713">18</offsets></xref><offsets xml_i="19238" xml_f="19659" txt_i="11713" txt_f="12134">]. However, no significant changes in lung function were seen between the start and end of the study and on comparison between groups. It is possible that this is due to the relatively small group numbers or that a longer follow-up period is required. The prevalence of diabetes mellitus amongst the groups was similar; its presence has recently been associated with a more rapid decline in lung function in CF patients [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="19690" xml_f="19691" txt_i="12134" txt_f="12135">6</offsets></xref><offsets xml_i="19698" xml_f="19808" txt_i="12135" txt_f="12245">]. Surprisingly, the incidence of smoking was highest amongst those with more severe disease in the BCC group.</offsets></p><p><offsets xml_i="19815" xml_f="19972" txt_i="12246" txt_f="12403">Investigators have shown evidence of this type of risk taking behaviour in these patients, however it is actually lower when compared than their peer group [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="20004" xml_f="20006" txt_i="12403" txt_f="12405">19</offsets></xref><offsets xml_i="20013" xml_f="20120" txt_i="12405" txt_f="12512">]. This emphasizes the importance of addressing relevant risk factors and behaviour amongst these patients.</offsets></p></sec><sec><title><offsets xml_i="20142" xml_f="20152" txt_i="12514" txt_f="12524">Conclusion</offsets></title><p><offsets xml_i="20163" xml_f="20480" txt_i="12525" txt_f="12842">Patients with BCC and PA infection have a similar use of antibiotics. Total numbers of organisms isolated and numbers of co-infecting organisms are significantly higher in the BCC group compared to PA, and in the PA group compared to NI patients. Types of co-infecting organisms are similar in all groups of patients.</offsets></p></sec><sec><title><offsets xml_i="20502" xml_f="20515" txt_i="12844" txt_f="12857">Abbreviations</offsets></title><p><offsets xml_i="20526" xml_f="20558" txt_i="12858" txt_f="12890">BCC Burkholderia cepacia complex</offsets></p><p><offsets xml_i="20565" xml_f="20583" txt_i="12891" txt_f="12909">CF Cystic fibrosis</offsets></p><p><offsets xml_i="20590" xml_f="20593" txt_i="12910" txt_f="12913">FEV</offsets><sub><offsets xml_i="20598" xml_f="20600" txt_i="12913" txt_f="12915">1 </offsets></sub><offsets xml_i="20606" xml_f="20644" txt_i="12915" txt_f="12953">Forced expiratory volume in one second</offsets></p><p><offsets xml_i="20651" xml_f="20678" txt_i="12954" txt_f="12981">NI 'Neither Isolated' group</offsets></p><p><offsets xml_i="20685" xml_f="20695" txt_i="12982" txt_f="12992">No. Number</offsets></p><p><offsets xml_i="20702" xml_f="20715" txt_i="12993" txt_f="13006">P Probability</offsets></p><p><offsets xml_i="20722" xml_f="20747" txt_i="13007" txt_f="13032">PA Pseudomonas aeruginosa</offsets></p><p><offsets xml_i="20754" xml_f="20757" txt_i="13033" txt_f="13036">SAO</offsets><sub><offsets xml_i="20762" xml_f="20764" txt_i="13036" txt_f="13038">2 </offsets></sub><offsets xml_i="20770" xml_f="20787" txt_i="13038" txt_f="13055">Oxygen Saturation</offsets></p><p><offsets xml_i="20794" xml_f="20815" txt_i="13056" txt_f="13077">SD Standard Deviation</offsets></p><p><offsets xml_i="20822" xml_f="20839" txt_i="13078" txt_f="13095">SE Standard Error</offsets></p><p><offsets xml_i="20846" xml_f="20894" txt_i="13096" txt_f="13144">SPSS Statistical Package for the Social Sciences</offsets></p><p><offsets xml_i="20901" xml_f="20920" txt_i="13145" txt_f="13164">SPECIAL CHARACTERS:</offsets></p><p><offsets xml_i="20927" xml_f="20941" txt_i="13165" txt_f="13176">&lt; Less than</offsets></p><p><offsets xml_i="20948" xml_f="20955" txt_i="13177" txt_f="13184">α Alpha</offsets></p></sec><sec><title><offsets xml_i="20977" xml_f="20996" txt_i="13186" txt_f="13205">Competing Interests</offsets></title><p><offsets xml_i="21007" xml_f="21066" txt_i="13206" txt_f="13265">The authors' declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="21088" xml_f="21110" txt_i="13267" txt_f="13289">Authors' Contributions</offsets></title><sec><title><offsets xml_i="21130" xml_f="21134" txt_i="13290" txt_f="13294">TMcM</offsets></title><p><offsets xml_i="21145" xml_f="21204" txt_i="13295" txt_f="13354">Collected data relating to the study and drafted the paper.</offsets></p></sec><sec><title><offsets xml_i="21226" xml_f="21230" txt_i="13356" txt_f="13360">AMcD</offsets></title><p><offsets xml_i="21241" xml_f="21334" txt_i="13361" txt_f="13454">Participated in the analysis of clinical specimens and contributed to the manuscript content.</offsets></p></sec><sec><title><offsets xml_i="21356" xml_f="21359" txt_i="13456" txt_f="13459">JEM</offsets></title><p><offsets xml_i="21370" xml_f="21420" txt_i="13460" txt_f="13510">Participated in the study design and coordination.</offsets></p></sec><sec><title><offsets xml_i="21442" xml_f="21445" txt_i="13512" txt_f="13515">JSE</offsets></title><p><offsets xml_i="21456" xml_f="21527" txt_i="13516" txt_f="13587">Conceived of the study and participated in its design and coordination.</offsets></p><p><offsets xml_i="21534" xml_f="21584" txt_i="13588" txt_f="13638">All authors read and approved the final manuscript</offsets></p></sec></sec></body><back><ack><sec><title>Acknowledgements</title><p>Dr Chris Patterson [Department Of Epidemiology, Queens University Belfast] performed the statistical analysis of all data.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Govan</surname><given-names>JR</given-names></name><name><surname>Nelson</surname><given-names>JW</given-names></name></person-group><article-title>Microbiology of lung infection in cystic fibrosis</article-title><source>Br Med Bull</source><year>1992</year><volume>48</volume><fpage>912</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">1281036</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>EL</given-names></name><name><surname>Ellis</surname><given-names>ME</given-names></name><name><surname>Webb</surname><given-names>AK</given-names></name><name><surname>Neal</surname><given-names>KR</given-names></name><name><surname>Dodd</surname><given-names>M</given-names></name><name><surname>Caul</surname><given-names>EO</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms</article-title><source>Thorax</source><year>1989</year><volume>44</volume><fpage>739</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">2588211</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>TT</given-names></name></person-group><article-title>Infection in patients with cystic fibrosis</article-title><source>Am J Med</source><year>1986</year><volume>81</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">3526881</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(86)90516-4</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name><name><surname>Carzino</surname><given-names>R</given-names></name><name><surname>Hull</surname><given-names>J</given-names></name><name><surname>Olinsky</surname><given-names>A</given-names></name><name><surname>Phelan</surname><given-names>PD</given-names></name></person-group><article-title>Severe viral respiratory infections in infants with cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>1998</year><volume>26</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">9888211</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maselli</surname><given-names>JH</given-names></name><name><surname>Sontag</surname><given-names>MK</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><name><surname>MacKenzie</surname><given-names>T</given-names></name><name><surname>Wagener</surname><given-names>JS</given-names></name><name><surname>Accurso</surname><given-names>FJ</given-names></name></person-group><article-title>Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening</article-title><source>Pediatr Pulmonol</source><year>2003</year><volume>35</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">12629621</pub-id><pub-id pub-id-type="doi">10.1002/ppul.10230</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaedel</surname><given-names>C</given-names></name><name><surname>de</surname><given-names>MI</given-names></name><name><surname>Hjelte</surname><given-names>L</given-names></name><name><surname>Johannesson</surname><given-names>M</given-names></name><name><surname>Kornfalt</surname><given-names>R</given-names></name><name><surname>Lindblad</surname><given-names>A</given-names></name><name><surname>Strandvik</surname><given-names>B</given-names></name><name><surname>Wahlgren</surname><given-names>L</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name></person-group><article-title>Predictors of deterioration of lung function in cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>2002</year><volume>33</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">12001283</pub-id><pub-id pub-id-type="doi">10.1002/ppul.10100</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tablan</surname><given-names>OC</given-names></name><name><surname>Chorba</surname><given-names>TL</given-names></name><name><surname>Schidlow</surname><given-names>DV</given-names></name><name><surname>White</surname><given-names>JW</given-names></name><name><surname>Hardy</surname><given-names>KA</given-names></name><name><surname>Gilligan</surname><given-names>PH</given-names></name><name><surname>Morgan</surname><given-names>WM</given-names></name><name><surname>Carson</surname><given-names>LA</given-names></name><name><surname>Martone</surname><given-names>WJ</given-names></name><name><surname>Jason</surname><given-names>JM</given-names></name><collab>.</collab></person-group><article-title>Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome</article-title><source>J Pediatr</source><year>1985</year><volume>107</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">4032134</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>JL</given-names></name><name><surname>Emerson</surname><given-names>J</given-names></name><name><surname>Stapp</surname><given-names>JR</given-names></name><name><surname>Yim</surname><given-names>DL</given-names></name><name><surname>Krzewinski</surname><given-names>J</given-names></name><name><surname>Louden</surname><given-names>L</given-names></name><name><surname>Ramsey</surname><given-names>BW</given-names></name><name><surname>Clausen</surname><given-names>CR</given-names></name></person-group><article-title>Microbiology of sputum from patients at cystic fibrosis centers in the United States</article-title><source>Clin Infect Dis</source><year>1998</year><volume>27</volume><fpage>158</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">9675470</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ledson</surname><given-names>MJ</given-names></name><name><surname>Gallagher</surname><given-names>MJ</given-names></name><name><surname>Jackson</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>CA</given-names></name><name><surname>Walshaw</surname><given-names>MJ</given-names></name></person-group><article-title>Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre</article-title><source>Thorax</source><year>2002</year><volume>57</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">11828044</pub-id><pub-id pub-id-type="doi">10.1136/thorax.57.2.142</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muhdi</surname><given-names>K</given-names></name><name><surname>Edenborough</surname><given-names>FP</given-names></name><name><surname>Gumery</surname><given-names>L</given-names></name><name><surname>O'Hickey</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>EG</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Stableforth</surname><given-names>DE</given-names></name></person-group><article-title>Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic</article-title><source>Thorax</source><year>1996</year><volume>51</volume><fpage>374</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">8733488</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>GM</given-names></name><name><surname>Armstrong</surname><given-names>DS</given-names></name><name><surname>Carzino</surname><given-names>R</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name><name><surname>Olinsky</surname><given-names>A</given-names></name><name><surname>Robertson</surname><given-names>CF</given-names></name><name><surname>Grimwood</surname><given-names>K</given-names></name></person-group><article-title>Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis</article-title><source>J Pediatr</source><year>2001</year><volume>138</volume><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11343046</pub-id><pub-id pub-id-type="doi">10.1067/mpd.2001.112897</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenstein</surname><given-names>BJ</given-names></name><name><surname>Zeitlin</surname><given-names>PL</given-names></name></person-group><article-title>Prognosis in cystic fibrosis</article-title><source>Curr Opin Pulm Med</source><year>1995</year><volume>1</volume><fpage>444</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">9363080</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>A</given-names></name><name><surname>Walters</surname><given-names>S</given-names></name></person-group><article-title>Prophylactic antibiotics for cystic fibrosis</article-title><source>Cochrane Database Syst Rev</source><year>2001</year><fpage>CD001912</fpage><pub-id pub-id-type="pmid">11687002</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Florea</surname><given-names>VG</given-names></name><name><surname>Bolger</surname><given-names>AP</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Florea</surname><given-names>ND</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name><name><surname>Hodson</surname><given-names>ME</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Henein</surname><given-names>MY</given-names></name></person-group><article-title>Wasting as an independent predictor of mortality in patients with cystic fibrosis</article-title><source>Thorax</source><year>2001</year><volume>56</volume><fpage>746</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">11562511</pub-id><pub-id pub-id-type="doi">10.1136/thorax.56.10.746</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hendry</surname><given-names>J</given-names></name><name><surname>Elborn</surname><given-names>JS</given-names></name><name><surname>Nixon</surname><given-names>L</given-names></name><name><surname>Shale</surname><given-names>DJ</given-names></name><name><surname>Webb</surname><given-names>AK</given-names></name></person-group><article-title>Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa</article-title><source>Eur Respir J</source><year>1999</year><volume>14</volume><fpage>435</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">10515426</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-3003.1999.14b32.x</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>JE</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><name><surname>Barclay</surname><given-names>GR</given-names></name><name><surname>Govan</surname><given-names>JR</given-names></name></person-group><article-title>Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia</article-title><source>Infect Immun</source><year>1997</year><volume>65</volume><fpage>4281</fpage><lpage>4287</lpage><pub-id pub-id-type="pmid">9317038</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchison</surname><given-names>ML</given-names></name><name><surname>Poxton</surname><given-names>IR</given-names></name><name><surname>Govan</surname><given-names>JR</given-names></name></person-group><article-title>Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes</article-title><source>Infect Immun</source><year>1998</year><volume>66</volume><fpage>2033</fpage><lpage>2039</lpage><pub-id pub-id-type="pmid">9573086</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>M</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name></person-group><article-title>Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>107</volume><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">11344348</pub-id><pub-id pub-id-type="doi">10.1067/mai.2001.114117</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Britto</surname><given-names>MT</given-names></name><name><surname>Garrett</surname><given-names>JM</given-names></name><name><surname>Dugliss</surname><given-names>MA</given-names></name><name><surname>Daeschner</surname><given-names>CWJ</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Leigh</surname><given-names>MW</given-names></name><name><surname>Majure</surname><given-names>JM</given-names></name><name><surname>Schultz</surname><given-names>WH</given-names></name><name><surname>Konrad</surname><given-names>TR</given-names></name></person-group><article-title>Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study</article-title><source>Pediatrics</source><year>1998</year><volume>101</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">9445499</pub-id><pub-id pub-id-type="doi">10.1542/peds.101.2.250</pub-id></citation></ref></ref-list></back></article>